DEF: INVO Fertility Seeks Shareholder Approval for Major Capital Restructuring

INVO Fertility, Inc. calls a special meeting to ratify a new auditor, approve significant share issuances for a private placement, and dramatically increase authorized common stock, amidst ongoing financial concerns.

Summary

• A Special Meeting of Stockholders will be held virtually on January 22, 2026, at 12 p.m. Eastern Time, with a record date of December 8, 2025.
• Stockholders will vote on the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ended December 31, 2025, following the dismissal of M&K CPAS, PLLC.
• M&K CPAS, PLLC's audit reports for fiscal years 2023 and 2024 contained an expression of substantial doubt regarding the Company's ability to continue as a going concern.
• Approval is sought for the issuance of up to 4,733,728 shares of common stock upon the exercise of a warrant issued in a private placement transaction that closed on December 4, 2025, as required by Nasdaq Listing Rule 5635.
• A proposal to amend the Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 6,250,000 to 250,000,000 will be voted upon.
• Stockholders will also consider approving a fourth amendment and restatement of the 2019 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder to a total of 1,000,000, approximately 10% of total issued and outstanding stock on a fully-diluted basis.
• An additional proposal seeks approval for any adjournments of the Special Meeting to solicit additional proxies if there are insufficient votes for the other proposals or to establish a quorum.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by a 'going concern' warning, consistent net losses, and extremely poor shareholder returns. While management is seeking to address capital needs and incentivize personnel, the proposed actions involve significant dilution, and the underlying business health remains highly questionable.

Positives

• Secured approximately $4,000,000 in a private placement transaction on December 4, 2025, providing capital through shares, pre-funded warrants, and a common stock purchase warrant.
• The Board of Directors recommends voting FOR all proposals, indicating internal alignment on these strategic actions to address capital needs and corporate flexibility.
• The company is actively seeking to strengthen its financial position and pursue growth initiatives like acquisitions through increased authorized shares, which could provide future opportunities.

Negatives

• The former auditor, M&K CPAS, PLLC, expressed 'substantial doubt regarding the Company's ability to continue as a going concern' in its audit reports for fiscal years ended December 31, 2023, and December 31, 2024.
• The company reported significant net losses for three consecutive years: $(9,053,676) in 2024, $(8,034,612) in 2023, and $(10,892,511) in 2022.
• Total Stockholder Return (TSR) has been extremely poor, with an initial $100 investment valued at only $10 in 2024, $16 in 2023, and $12 in 2022, indicating significant value destruction.
• The proposed increase in authorized common stock from 6,250,000 to 250,000,000 shares, and the issuance of up to 4,733,728 shares from a warrant, will have a significant dilutive effect on earnings per share, stockholder equity, and voting rights.
• Executive and director salaries were temporarily reduced in 2023, and significant amounts of executive and director compensation were deferred in 2024 and paid in 2025, suggesting cash flow constraints.

Risks

• Substantial doubt regarding the Company's ability to continue as a going concern, as noted by the former independent auditor, poses a fundamental risk to the company's existence.
• Significant dilution of existing stockholders' equity and voting rights is highly probable due to the proposed increase in authorized common stock to 250,000,000 shares and the issuance of up to 4,733,728 shares upon warrant exercise.
• Future sales of substantial amounts of common stock, or the perception that these sales might occur, could adversely affect the prevailing market price of common stock or limit the ability to raise additional capital.
• The availability of additional authorized shares for issuance may have the effect of discouraging a merger, tender offer, proxy contest, or other attempt to obtain control, potentially limiting strategic options.

Future Outlook

The company intends to use the increased authorized common stock for future financing transactions (public or private offerings), strategic investments, mergers, acquisitions, licenses, partnerships, collaborations, and other general corporate purposes. The company has committed to holding stockholder meetings every four months until approval for the warrant issuance is obtained.

Management Comments

• Our Board believes that it is in the best interests of our Company to increase the number of authorized shares of our common stock in order to give us greater flexibility in considering and planning for potential business needs and pursuing additional acquisitions, a key growth initiative for the Company.
• The Board believes that the availability of additional authorized shares of our common stock will afford us needed flexibility in acting upon financing transactions to strengthen our financial position and/or engaging in strategic activities without using cash.
• The purpose of the Plan is to further align the interests of employees, directors, and non-employee consultants with those of the stockholders by providing incentive compensation opportunities tied to the performance of the common stock and by promoting increased ownership of the common stock by such individuals.
• Our Board of Directors recommends that stockholders vote FOR approval of all proposals.

Industry Context

The filing does not provide specific industry context or trends. However, the need for significant capital raises, the 'going concern' warning, and the pursuit of acquisitions suggest a company in a challenging financial position within its sector, potentially seeking to consolidate or expand through M&A to achieve scale or profitability. The fertility industry is generally growing, so these issues appear company-specific rather than industry-wide.

Comparison to Industry Standards

• The 'going concern' opinion from the former auditor is a severe indicator of financial distress, which is significantly below industry standards for healthy, publicly traded companies.
• The negative net income for three consecutive years and the drastic decline in Total Stockholder Return (from $100 to $10 in 2024) are substantially worse than typical performance for established companies in any industry.
• The proposed increase in authorized shares by nearly 40x (from 6.25 million to 250 million) is an unusually large increase, potentially signaling a need for substantial future capital or a highly dilutive strategy, which would be an outlier compared to standard corporate finance practices for stable growth.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders face significant potential dilution from the proposed increase in authorized shares and the warrant exercise. The 'going concern' warning indicates high risk to investment value, compounded by poor historical Total Stockholder Return.
• Employees and management benefit from the proposed increase in the stock incentive plan, which aims to attract and retain talent. Executive compensation includes base salaries, bonuses, and equity awards, with some deferrals in 2024.
• Creditors face increased risk due to the 'going concern' warning. The capital raise and efforts to strengthen the financial position could potentially improve the company's ability to meet its obligations, but the underlying financial health remains a concern.
• Customers and suppliers are not directly mentioned, but a financially distressed company could face challenges in operations that might indirectly affect these groups.

Next Steps

• Stockholders are to vote on the five proposals at the Special Meeting on January 22, 2026.
• The company expects to file a current report on Form 8-K within four business days after the Special Meeting to announce preliminary or final voting results.
• If stockholder approval for the warrant issuance is not obtained, the company will call a meeting every four months thereafter to seek such approval until it is obtained or the warrant is no longer outstanding.
• If the common stock increase proposal is approved, the company intends to file the certificate of amendment with the Secretary of State of Nevada as soon as practicable after the Special Meeting.

Key Dates

Recommendation

The company's financial health is severely compromised, as evidenced by the 'substantial doubt regarding the Company's ability to continue as a going concern' from its former auditor, consistent multi-million dollar net losses, and a drastic decline in Total Stockholder Return. While the company is attempting to raise capital and incentivize management, the proposed actions, particularly the massive increase in authorized shares and warrant issuances, will lead to significant dilution for existing shareholders. The fundamental business appears to be in deep distress, making it a high-risk investment with a strong likelihood of further value erosion.

Keywords

INVO Fertility, IVF, Proxy Statement, DEF 14A, Shareholder Meeting, Stock Authorization, Warrant Issuance, Stock Incentive Plan, Corporate Governance, Auditor Ratification, Going Concern, Dilution, Private Placement, Nasdaq Listing Rule 5635, Executive Compensation